AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 182 min read$LABT

A new gel for infected diabetic foot ulcers is ready for a clinical trial

Lakewood-Amedex Biotherapeutics (LABT) received approvals to start a Phase 2a trial for Nu-3, a gel treating infected diabetic foot ulcers. The trial follows positive preclinical data and aligns with federal antimicrobial resistance mandates. LABT stock rose 3.55% on the news, with heavy trading volume.

Original reporting
stocktitan.net
Published Sep 18, 2026, 12:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 12:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$LABT
Bullish
medium confidence
Mentioned
$LABT
Relevance
7/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$LABTBullishMed
01

Why it matters

The IRB approval enables the first human efficacy assessment, a key catalyst for the company's pipeline and valuation.

02

Market read

First‑time trial start news for a micro‑cap biotech; likely to generate short‑term price movement.

03

What to watch

Funding runway and competition from larger antibiotic developers could constrain long‑term upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Lakewood-Amedex Biotherapeutics is a clinical‑stage company developing broad‑spectrum antimicrobials. The Nu-3 gel targets infected diabetic foot ulcers, a high‑need indication.

Company-level read

Ticker impact

$LABTBullishMedium confidence
Context

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) received IRB approval and is ready to start its Phase 2a trial of Nu-3 for infected diabetic foot ulcers.

Expected impact

Potential upside of 5‑10% over the next week if early data appear positive.

Evidence & confidence

Biotech stocks often rally on trial start announcements, especially when the market reaction is already positive (+3.55%).

Market effects

Sector

Highlights growing interest in antimicrobial‑resistant therapies, may benefit other biotech firms in the anti‑infection space.

Regional

US biotech sector sees modest boost; limited broader market effect.

Global

Limited to investors tracking clinical‑stage biotech developments.

Counterpoint

What could challenge this read

Trial may face delays or negative data; early hype could be premature.

Key entities

  • company
    Lakewood-Amedex Biotherapeutics Inc.

    Clinical‑stage biotech developing the Bisphosphocin® class of antimicrobials.

  • product
    Nu-3

    Proprietary topical gel intended to treat infected diabetic foot ulcers.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 21
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and clinical site readiness to start a Phase 2a trial for its lead product, Nu-3, treating infected diabetic foot ulcers. The trial aims to evaluate Nu-3's safety and efficacy, building on positive preclinical data. The company aims to address antibiotic-resistant bacterial strains with its Bisphosphocin® class of antimicrobials.

insidermonkey.com2 min
SEP 18
$LABTMedAI 8/10

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) received IRB approvals and confirmed clinical site readiness to start a Phase 2a trial for Nu-3, a treatment for infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy, building on positive preclinical data. The company focuses on addressing antibiotic-resistant bacterial infections with its Bisphosphocin® class of antimicrobials.

morningstar.com1 min
JUL 15
$LABTMed

Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel

Lakewood-Amedex Biotherapeutics (NASDAQ: LABT) said preclinical safety data for its Nu-3 topical gel supported dose selection for an upcoming Phase 2a trial in infected diabetic foot ulcers. The company reported Nu-3 was well tolerated in an FDA-required safety study at higher doses, with low systemic exposure and no wound-healing inhibition. Planned gel concentrations are 2%, 5%, and 10%.

prnewswire.com3 min
SEP 21
$AMZNHighAI 9/10

1.58-million-staff Amazon will soon have more Nvidia GPUs than employees — AWS to buy more than 3 million additional chips before 2029 in addition to thousands of existing H100, H200

Amazon's AWS division plans to buy over 3 million Nvidia GPUs by 2029, including 2 million Blackwell Ultra, Rubin, and Rubin Ultra GPUs. This follows a previous commitment of over 1 million GPUs. Amazon has approximately 1.58 million employees, with a smaller share working in AWS data centers. The deal includes 100,000 GPUs for US government AI workloads. AWS revenue grew 37% year over year to $42.2 billion in Q2.

techradar.com2 min